What are the indications for corticosteroid use during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Indications of Corticosteroids in Pregnancy

Corticosteroids in pregnancy are primarily indicated for fetal lung maturation in women at risk of preterm delivery before 37 weeks of gestation, with the strongest evidence supporting use between 34 0/7 and 36 6/7 weeks for those at high risk of delivery within 7 days. 1

Primary Indication: Fetal Lung Maturation for Preterm Birth

Late Preterm Period (34 0/7 to 36 6/7 weeks)

Offer a single course of betamethasone (2 doses of 12 mg IM, 24 hours apart) to patients with: 1

  • Singleton pregnancy between 34 0/7 and 36 6/7 weeks
  • High probability of delivery within 7 days and before 37 weeks, defined as:
    • Preterm labor with intact membranes AND cervical dilation ≥3 cm OR ≥75% effacement
    • Spontaneous rupture of membranes
    • Planned delivery within 24 hours to 7 days for maternal/fetal indications (preeclampsia, fetal growth restriction, oligohydramnios)

This recommendation carries GRADE 1A evidence—the highest quality available. 1

Earlier Preterm Period (24 to 34 weeks)

Antenatal corticosteroids substantially reduce neonatal death, respiratory distress syndrome, intraventricular hemorrhage, and sepsis when administered to women at risk of preterm delivery before 34 weeks. 1, 2 A single course is recommended for women between 24-34 weeks at risk of delivery within 7 days. 2

Preterm Premature Rupture of Membranes (PPROM)

Administer corticosteroids to women with PPROM before 32 weeks of gestation to reduce respiratory distress syndrome, perinatal mortality, and other morbidities. 2 Evidence for efficacy at 32-33 weeks is less clear but treatment may be beneficial, particularly with documented pulmonary immaturity. 2

Special Populations and Considerations

Consider Use (Weaker Evidence):

  • Multiple gestations reduced to singleton on or after 14 0/7 weeks 1
  • Pregnancies with fetal anomalies 1
  • Expected delivery in <12 hours 1

These carry GRADE 2C recommendations, reflecting lower quality evidence. 1

Contraindications and Cautions

Do NOT use late preterm corticosteroids in women with pregestational diabetes mellitus due to increased risk of neonatal hypoglycemia, which independently associates with developmental delays. 1 This is a GRADE 1C recommendation. 1

Do NOT use corticosteroids when:

  • Low likelihood of delivery before 37 weeks (GRADE 1B) 1
  • Before fetal viability—sparse data exist and use is not recommended 2

Secondary Indications (Non-Fetal Lung Maturation)

Hyperemesis Gravidarum

Corticosteroids may be used for severe nausea and vomiting in pregnancy/hyperemesis gravidarum when other antiemetics fail. First-trimester corticosteroid use is not associated with increased risk of congenital malformations, orofacial clefting, cardiac defects, or hypospadias. 3 However, data are limited to approximately 3,500 first-trimester exposures. 3

Maternal Autoimmune/Inflammatory Conditions

Corticosteroid therapy is appropriate to control clinically active maternal illness during pregnancy. 4 Pregnant women receiving corticosteroids experience the same benefits and side effects as non-pregnant women. 4 Clinical experience suggests no abnormalities in children of mothers treated with usual doses of prednisone or methylprednisolone throughout pregnancy, though premature rupture of membranes and low birthweight may occur. 4

Other Maternal Conditions

Real-world data show respiratory and skin diseases are the most common indications for oral corticosteroid use during pregnancy, with methylprednisolone and prednisolone accounting for 90% of use. 5 Recent evidence shows oral corticosteroid exposure during pregnancy is not associated with increased risk of gestational diabetes (except modest increase at 4-6 weeks gestation). 6

Dosing and Administration

Standard regimen: Betamethasone 12 mg IM, two doses 24 hours apart 1

Rescue course: May consider a single rescue course if:

  • Prior treatment was >2 weeks ago
  • Gestational age <32 6/7 weeks
  • Delivery likely within next week 2

Do NOT use: Regularly scheduled repeat courses or multiple courses (>2) are not recommended. 2

Critical Safety Monitoring

Counseling Requirements

Thoroughly counsel patients at risk for late preterm delivery regarding potential risks and benefits, emphasizing that long-term risks remain uncertain (GRADE 1C). 1 This is particularly important given emerging concerns about lasting epigenetic changes and potential adverse neurodevelopmental outcomes. 7

Timing Optimization

The optimal therapeutic window is 24 hours to 7 days before delivery. 8 In practice, only 19% of women deliver within this optimal window, with mean interval of 31 days from administration to delivery. 8 Notably, 29% of women receiving antenatal corticosteroids ultimately deliver at term. 8

Common Pitfalls to Avoid

  1. Overuse in low-risk populations: Do not administer to women with low likelihood of preterm delivery—this leads to unnecessary fetal exposure 1

  2. Use in diabetic patients: Avoid late preterm corticosteroids in pregestational diabetes due to compounded hypoglycemia risk 1

  3. Multiple courses: Resist the temptation for regularly scheduled repeat courses beyond a single rescue dose 2

  4. Inadequate timing assessment: Carefully evaluate actual delivery risk by specific indication—optimal timing varies significantly (preeclampsia 40%, PPROM 31%, threatened preterm labor only 6%) 8

  5. Low-resource settings: Growing evidence suggests potential for increased neonatal mortality and maternal morbidity with antenatal corticosteroids in low-resource environments, highlighting the need for context-specific application 7

References

3
Guideline

the management of nausea and vomiting in pregnancy and hyperemesis gravidarum (green-top guideline no. 69).

BJOG : an international journal of obstetrics and gynaecology, 2024

4
Research

Corticosteroids during pregnancy.

Scandinavian journal of rheumatology. Supplement, 1998

7
Research

The clinical use of corticosteroids in pregnancy.

Human reproduction update, 2016

Related Questions

What oral glucocorticoid alternatives are safe in pregnancy to replace hydrocortisone tablets for cortisol replacement?
What is the appropriate management plan for a 58-year-old female with a 17-year history of chronic cough after pneumonia, intermittent sputum production, dyspnea on exertion, nicotine dependence with a 48 pack‑year smoking history (currently smoking ~1 pack every two weeks), who is not on inhalers and requires smoking cessation therapy, a short‑acting bronchodilator inhaler, a 14‑day course of nebulized ipratropium bromide, a cough suppressant, a chest radiograph, and glucose monitoring before a corticosteroid injection?
What is the ACOG‑recommended dose of vaginal terconazole for a pregnant woman at 16 weeks gestation?
In an adult with an acute cough from a viral or uncomplicated bacterial respiratory infection, what is the recommended treatment and how do dexamethasone and prednisone compare for short‑course corticosteroid therapy?
In a 45-year-old man with severe sepsis from multifocal pneumonia, who is intubated, hypotensive on vasopressors, anuric, volume overloaded, hyperkalemic, and acidotic with markedly elevated creatinine and BUN, what is the preferred renal replacement therapy?
What is the appropriate self‑monitoring of blood glucose for a patient with type 2 diabetes mellitus who is treated only with oral medications?
What is the appropriate treatment for temporomandibular joint (TMJ) dysfunction during pregnancy?
In a 53-year-old female who was on phenytoin 100 mg twice daily and started levetiracetam 500 mg twice daily one week ago, now presenting with dizziness and vertigo, what is the likely diagnosis and appropriate treatment?
How should magnesium sulfate be administered after completing a potassium phosphate infusion?
In a patient with type 2 diabetes who is taking basal insulin, how often should blood glucose be monitored and how should the insulin dose be adjusted?
What is the appropriate intravenous hydrocortisone dose for an adult with recurrent urticaria that is not responding to antihistamines?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.